vs
MIDDLEBY Corp（MIDD）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
MIDDLEBY Corp的季度营收约是Revvity的1.1倍（$866.4M vs $772.1M），Revvity净利率更高（12.7% vs 4.3%，领先8.5%），Revvity同比增速更快（5.9% vs -30.6%），MIDDLEBY Corp自由现金流更多（$165.5M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs -3.3%）
美国Middleby公司是总部位于伊利诺伊州埃尔金的上市企业，主营商用烹饪设备、工业加工设备及民用家电，其商用烹饪设备业务覆盖美国及全球前100家餐饮连锁品牌中的97家，是全球餐饮设备领域的领先供应商。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
MIDD vs RVTY — 直观对比
营收规模更大
MIDD
是对方的1.1倍
$772.1M
营收增速更快
RVTY
高出36.4%
-30.6%
净利率更高
RVTY
高出8.5%
4.3%
自由现金流更多
MIDD
多$3.7M
$161.8M
两年增速更快
RVTY
近两年复合增速
-3.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $866.4M | $772.1M |
| 净利润 | $36.9M | $98.4M |
| 毛利率 | 38.8% | — |
| 营业利润率 | 17.3% | 14.5% |
| 净利率 | 4.3% | 12.7% |
| 营收同比 | -30.6% | 5.9% |
| 净利润同比 | -67.1% | 3.9% |
| 每股收益（稀释后） | $0.74 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MIDDRVTY
| Q4 25 | $866.4M | $772.1M | ||
| Q3 25 | $982.1M | $698.9M | ||
| Q2 25 | $977.9M | $720.3M | ||
| Q1 25 | $906.6M | $664.8M | ||
| Q4 24 | $1.0B | $729.4M | ||
| Q3 24 | $942.8M | $684.0M | ||
| Q2 24 | $991.5M | $691.7M | ||
| Q1 24 | $926.9M | $649.9M |
净利润MIDDRVTY
| Q4 25 | $36.9M | $98.4M | ||
| Q3 25 | $-513.0M | $46.7M | ||
| Q2 25 | $106.0M | $53.9M | ||
| Q1 25 | $92.4M | $42.2M | ||
| Q4 24 | $112.3M | $94.6M | ||
| Q3 24 | $114.2M | $94.4M | ||
| Q2 24 | $115.4M | $55.4M | ||
| Q1 24 | $86.6M | $26.0M |
毛利率MIDDRVTY
| Q4 25 | 38.8% | — | ||
| Q3 25 | 36.8% | 53.6% | ||
| Q2 25 | 38.0% | 54.5% | ||
| Q1 25 | 38.2% | 56.5% | ||
| Q4 24 | 38.4% | — | ||
| Q3 24 | 37.7% | 56.3% | ||
| Q2 24 | 38.3% | 55.7% | ||
| Q1 24 | 37.4% | 54.6% |
营业利润率MIDDRVTY
| Q4 25 | 17.3% | 14.5% | ||
| Q3 25 | -56.4% | 11.7% | ||
| Q2 25 | 15.9% | 12.6% | ||
| Q1 25 | 15.5% | 10.9% | ||
| Q4 24 | 16.8% | 16.3% | ||
| Q3 24 | 18.4% | 14.3% | ||
| Q2 24 | 17.7% | 12.4% | ||
| Q1 24 | 14.8% | 6.8% |
净利率MIDDRVTY
| Q4 25 | 4.3% | 12.7% | ||
| Q3 25 | -52.2% | 6.7% | ||
| Q2 25 | 10.8% | 7.5% | ||
| Q1 25 | 10.2% | 6.4% | ||
| Q4 24 | 11.1% | 13.0% | ||
| Q3 24 | 12.1% | 13.8% | ||
| Q2 24 | 11.6% | 8.0% | ||
| Q1 24 | 9.3% | 4.0% |
每股收益（稀释后）MIDDRVTY
| Q4 25 | $0.74 | $0.86 | ||
| Q3 25 | $-10.15 | $0.40 | ||
| Q2 25 | $1.99 | $0.46 | ||
| Q1 25 | $1.69 | $0.35 | ||
| Q4 24 | $2.07 | $0.77 | ||
| Q3 24 | $2.11 | $0.77 | ||
| Q2 24 | $2.13 | $0.45 | ||
| Q1 24 | $1.59 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $222.2M | $919.9M |
| 总债务越低越好 | $2.2B | — |
| 股东权益账面价值 | $2.8B | $7.3B |
| 总资产 | $6.3B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.78× | — |
8季度趋势，按日历期对齐
现金及短期投资MIDDRVTY
| Q4 25 | $222.2M | $919.9M | ||
| Q3 25 | $175.1M | $931.4M | ||
| Q2 25 | $511.5M | $991.8M | ||
| Q1 25 | $745.1M | $1.1B | ||
| Q4 24 | $689.5M | $1.2B | ||
| Q3 24 | $606.0M | $1.2B | ||
| Q2 24 | $459.5M | $2.0B | ||
| Q1 24 | $341.0M | $1.7B |
总债务MIDDRVTY
| Q4 25 | $2.2B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益MIDDRVTY
| Q4 25 | $2.8B | $7.3B | ||
| Q3 25 | $2.9B | $7.4B | ||
| Q2 25 | $3.6B | $7.6B | ||
| Q1 25 | $3.7B | $7.6B | ||
| Q4 24 | $3.6B | $7.7B | ||
| Q3 24 | $3.6B | $7.9B | ||
| Q2 24 | $3.4B | $7.9B | ||
| Q1 24 | $3.3B | $7.8B |
总资产MIDDRVTY
| Q4 25 | $6.3B | $12.2B | ||
| Q3 25 | $6.4B | $12.1B | ||
| Q2 25 | $7.3B | $12.4B | ||
| Q1 25 | $7.4B | $12.4B | ||
| Q4 24 | $7.3B | $12.4B | ||
| Q3 24 | $7.2B | $12.8B | ||
| Q2 24 | $7.0B | $13.4B | ||
| Q1 24 | $6.9B | $13.4B |
负债/权益比MIDDRVTY
| Q4 25 | 0.78× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.66× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $165.5M | $161.8M |
| 自由现金流率自由现金流/营收 | 19.1% | 21.0% |
| 资本支出强度资本支出/营收 | 1.5% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $530.1M | $509.4M |
8季度趋势，按日历期对齐
经营现金流MIDDRVTY
| Q4 25 | — | $182.0M | ||
| Q3 25 | $176.3M | $138.5M | ||
| Q2 25 | $122.0M | $134.3M | ||
| Q1 25 | $141.1M | $128.2M | ||
| Q4 24 | $239.7M | $174.2M | ||
| Q3 24 | $156.7M | $147.9M | ||
| Q2 24 | $149.5M | $158.6M | ||
| Q1 24 | $140.9M | $147.6M |
自由现金流MIDDRVTY
| Q4 25 | $165.5M | $161.8M | ||
| Q3 25 | $156.1M | $120.0M | ||
| Q2 25 | $101.1M | $115.5M | ||
| Q1 25 | $107.4M | $112.2M | ||
| Q4 24 | $226.6M | $149.8M | ||
| Q3 24 | $145.2M | $125.6M | ||
| Q2 24 | $138.6M | $136.6M | ||
| Q1 24 | $127.2M | $129.7M |
自由现金流率MIDDRVTY
| Q4 25 | 19.1% | 21.0% | ||
| Q3 25 | 15.9% | 17.2% | ||
| Q2 25 | 10.3% | 16.0% | ||
| Q1 25 | 11.8% | 16.9% | ||
| Q4 24 | 22.3% | 20.5% | ||
| Q3 24 | 15.4% | 18.4% | ||
| Q2 24 | 14.0% | 19.7% | ||
| Q1 24 | 13.7% | 20.0% |
资本支出强度MIDDRVTY
| Q4 25 | 1.5% | 2.6% | ||
| Q3 25 | 2.1% | 2.6% | ||
| Q2 25 | 2.1% | 2.6% | ||
| Q1 25 | 3.7% | 2.4% | ||
| Q4 24 | 1.3% | 3.4% | ||
| Q3 24 | 1.2% | 3.3% | ||
| Q2 24 | 1.1% | 3.2% | ||
| Q1 24 | 1.5% | 2.7% |
现金转化率MIDDRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | 1.15× | 2.49× | ||
| Q1 25 | 1.53× | 3.03× | ||
| Q4 24 | 2.13× | 1.84× | ||
| Q3 24 | 1.37× | 1.57× | ||
| Q2 24 | 1.30× | 2.87× | ||
| Q1 24 | 1.63× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MIDD
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
